Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
Renal Cell Carcinoma
OTHER: Non-Interventional
Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC), All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs., Up to 63 months|Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC, Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated., Up to 63 months|Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC, All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs., Up to 63 months|Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC, Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated., Up to 63 months
Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC, MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period., Up to 63 months|Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC, MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period., Up to 63 months
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents